Detalles de la búsqueda
1.
A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
BMC Cancer
; 18(1): 817, 2018 Aug 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30103729
2.
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
Acta Oncol
; 57(1): 67-73, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29202611
3.
A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.
Acta Oncol
; 56(9): 1161-1167, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28488912
4.
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Breast Cancer Res Treat
; 149(3): 715-26, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25667100
5.
Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Breast Cancer Res Treat
; 154(3): 483-94, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26585578
6.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
BMC Cancer
; 15: 239, 2015 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-25885472
7.
Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase.
Biochim Biophys Acta
; 1833(1): 40-7, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23085504
8.
Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
Breast Cancer Res
; 15(6): R119, 2013 Dec 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-24355041
9.
Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.
Breast Cancer Res Treat
; 139(1): 71-80, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23609470
10.
TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.
Tumour Biol
; 34(6): 3839-51, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23881388
11.
NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
Breast Cancer Res Treat
; 135(1): 67-78, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22527100
12.
Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.
Acta Oncol
; 51(6): 781-9, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22462654
13.
Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer.
Breast Cancer Res Treat
; 128(1): 165-70, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21516302
14.
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
NPJ Breast Cancer
; 7(1): 2, 2021 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33398005
15.
Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.
Breast Cancer Res Treat
; 121(3): 601-13, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19697122
16.
Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity.
Nutr Cancer
; 62(1): 122-31, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20043267
17.
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Breast Cancer Res
; 11(1): R11, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19239686
18.
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Breast Cancer Res Treat
; 114(2): 263-75, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18409071
19.
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
BMC Cancer
; 9: 185, 2009 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-19531212
20.
The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells.
Anticancer Drugs
; 20(8): 723-35, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19584708